Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice.

Complement alternative pathway Complement deposition Complement factor H Human amnion epithelial cells Renal glomeruli

Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
10 06 2021
Historique:
received: 06 04 2021
accepted: 12 05 2021
entrez: 11 6 2021
pubmed: 12 6 2021
medline: 13 7 2021
Statut: epublish

Résumé

Complement factor H (FH) is the main plasma regulator of the alternative pathway of complement. Genetic and acquired abnormalities in FH cause uncontrolled complement activation amplifying, with the consequent accumulation of complement components on the renal glomeruli. This leads to conditions such as C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS). There is no effective therapy for these diseases. Half of the patients progress to end-stage renal disease and the condition recurs frequently in transplanted kidneys. Combined liver/kidney transplantation is a valid option for these patients, but the risks of the procedure and donor organ shortages hamper its clinical application. Therefore, there is an urgent need for alternative strategies for providing a normal FH supply. Human amnion epithelial cells (hAEC) have stem cell characteristics, including the capability to differentiate into hepatocyte-like cells in vivo.Here, we administered hAEC into the livers of newborn Cfh

Identifiants

pubmed: 34112227
doi: 10.1186/s13287-021-02386-7
pii: 10.1186/s13287-021-02386-7
pmc: PMC8194190
doi:

Substances chimiques

Complement C3 0
Complement Factor H 80295-65-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

332

Références

J Obstet Gynaecol Res. 2014 Feb;40(2):360-8
pubmed: 24245961
J Am Soc Nephrol. 2007 Sep;18(9):2447-56
pubmed: 17675665
Clin Exp Immunol. 2008 Feb;151(2):210-30
pubmed: 18190458
Stem Cells Transl Med. 2017 Jul;6(7):1583-1594
pubmed: 28585336
Hepatology. 2011 May;53(5):1719-29
pubmed: 21374689
Nat Genet. 2002 Aug;31(4):424-8
pubmed: 12091909
Kidney Int. 2010 Aug;78(3):279-86
pubmed: 20445496
Adv Immunol. 2009;104:115-49
pubmed: 20457117
J Gastroenterol Hepatol. 2015 Nov;30(11):1673-82
pubmed: 25973537
Nat Rev Nephrol. 2019 Mar;15(3):129-143
pubmed: 30692664
Hepatology. 2013 Mar;57(3):1017-23
pubmed: 23175463
Mol Genet Metab. 2013 Jun;109(2):132-8
pubmed: 23566440
Orphanet J Rare Dis. 2011 Sep 08;6:60
pubmed: 21902819
Mol Immunol. 2015 Sep;67(1):12-20
pubmed: 25824240
Cell Mol Immunol. 2006 Oct;3(5):333-40
pubmed: 17092430
Semin Nephrol. 2013 Nov;33(6):479-92
pubmed: 24161035
J Am Soc Nephrol. 2018 Jun;29(6):1649-1661
pubmed: 29588430
Pediatr Nephrol. 2016 May;31(5):759-68
pubmed: 26604087
Kidney Int. 2015 Dec;88(6):1314-1322
pubmed: 26221753
Placenta. 2017 Nov;59:139-145
pubmed: 28411944
Am J Kidney Dis. 2019 Aug;74(2):224-238
pubmed: 30929851

Auteurs

Federica Casiraghi (F)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy. federica.casiraghi@marionegri.it.

Pamela Yossenaidy Rodriguez Ordonez (PYR)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Nadia Azzollini (N)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Marta Todeschini (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Daniela Rottoli (D)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Roberta Donadelli (R)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Roberto Gramignoli (R)

Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden.

Ariela Benigni (A)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Marina Noris (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Giuseppe Remuzzi (G)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via GB Camozzi 3, 24020, Ranica, Bergamo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH